Sphingolipid Profiling: A Promising Tool for Stratifying the Metabolic Syndrome-Associated Risk

Simple item page
dc.catalogadoryvc
dc.contributor.authorBerkowitz Fiebich, Loni
dc.contributor.authorCabrera Reyes, Fernanda Estefania
dc.contributor.authorSalazar Vilches, Cristian Javier
dc.contributor.authorRyff, Carol D.
dc.contributor.authorCoe, Christopher
dc.contributor.authorRigotti Rivera, Attilio Gianpietro
dc.date.accessioned2024-12-30T19:09:27Z
dc.date.available2024-12-30T19:09:27Z
dc.date.issued2022
dc.description.abstractMetabolic syndrome (MetS) is a multicomponent risk condition that reflects the clustering of individual cardiometabolic risk factors related to abdominal obesity and insulin resistance. MetS increases the risk for cardiovascular diseases (CVD) and type 2 diabetes mellitus (T2DM). However, there still is not total clinical consensus about the definition of MetS, and its pathophysiology seems to be heterogeneous. Moreover, it remains unclear whether MetS is a single syndrome or a set of diverse clinical conditions conferring different metabolic and cardiovascular risks. Indeed, traditional biomarkers alone do not explain well such heterogeneity or the risk of associated diseases. There is thus a need to identify additional biomarkers that may contribute to a better understanding of MetS, along with more accurate prognosis of its various chronic disease risks. To fulfill this need, omics technologies may offer new insights into associations between sphingolipids and cardiometabolic diseases. Particularly, ceramides -the most widely studied sphingolipid class- have been shown to play a causative role in both T2DM and CVD. However, the involvement of simple glycosphingolipids remains controversial. This review focuses on the current understanding of MetS heterogeneity and discuss recent findings to address how sphingolipid profiling can be applied to better characterize MetS-associated risks.
dc.description.funderNational Fund of Scientific and Technological Development (Postdoctoral FONDECYT Grant #3210391)
dc.description.funderGovernment of Chile. Fondecyt Grant #1201607
dc.description.funderNational Institute on Aging Grant #P01 AG020166
dc.fechaingreso.objetodigital2024-12-30
dc.format.extent12 páginas
dc.fuente.origenWoS
dc.identifier.doi10.3389/fcvm.2021.785124
dc.identifier.issn2297-055X
dc.identifier.pubmedidMedline_Id: 35097004
dc.identifier.urihttps://doi.org/10.3389/fcvm.2021.785124
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/89387
dc.identifier.wosidWoS_Id: 000750150000001
dc.information.autorucEscuela de Medicina; Berkowitz Fiebich, Loni; S/I; 172010
dc.information.autorucEscuela de Medicina; Cabrera Reyes, Fernanda Estefania; S/I; 224244
dc.information.autorucEscuela de Medicina; Salazar Vilches, Cristian Javier; S/I; 1089229
dc.information.autorucEscuela de Medicina; Rigotti Rivera, Attilio Gianpietro; 0000-0002-0495-3525; 68489
dc.language.isoen
dc.nota.accesocontenido completo
dc.publisherFrontiers Media SA
dc.rightsacceso abierto
dc.subjectSphingolipids
dc.subjectCardiovascular risk (CVD)
dc.subjectCeramides
dc.subjectMetabolic syndrome
dc.subjectType 2 diabetes
dc.subjectLow-Density-Lipoprotein
dc.subjectCardiovascular Disease Mortality
dc.subjectPlasma Ceramides
dc.subjectInsulin Resistance
dc.subjectHeart Disease
dc.subjectDe-Novo
dc.subjectLactoslceramide
dc.subjectLipidomics
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleSphingolipid Profiling: A Promising Tool for Stratifying the Metabolic Syndrome-Associated Risk
dc.typeartículo
dc.volumen8
sipa.codpersvinculados172010
sipa.codpersvinculados224244
sipa.codpersvinculados1089229
sipa.codpersvinculados68489
sipa.trazabilidadWoS;18-03-2022
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fcvm-08-785124 (1).pdf
Size:
736.79 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas